• BudCars CEO featured guest during “Cannabis Talk 101” show
• SGMD partnership allowed company to “focus on growth”
• Walker recognizes Sugarmade’s great accounting, management team

The history and future of BudCars Cannabis Delivery Service was spotlighted during a recent “Cannabis Talk 101” episode. BudCars founder and CEO Clinton Walker was a featured guest on the global podcast, which is broadcast on major media networks and top podcast distribution hubs. The impressive potential for BudCars bodes well for Sugarmade (OTCQB: SGMD), which has invested in the burgeoning business.

“We are a Northern California premier cannabis delivery [service],” explained Walker, during the program. “We procure some of the best flower, edibles, concentrate. We make sure that we deliver them with great service, good quality. And we’ve got some good news for the listeners on the air today: LA, here we come.”

Walker started BudCars about nine months ago; the fledgling company has already gained approximately 18,000 customers. “To get started in the business, it’s a navigation of legal paperwork, bureaucracy, getting a type 9 license in the state of California,” he explained, noting that the company also obtained a fleet of vehicles (Toyota Priuses to maintain the company’s green footprint) and hired dispatchers and drivers.

Finally, the company procured a menu by “listening to [our] customer,” Walker said. “We started with about 15 SKUs. . . and now we have about 350.”

During the program, Walker discussed the upcoming opening of LA BudCars as well as the company’s planned expansion around the state, powered by the managerial expertise and capital power afforded by its Sugarmade partnership.

“There’s been a lot going on,” he said. “A great publicly traded company called Sugarmade got on board with us back in February of this year, brought in a great accounting and management team. They brought in a team that allowed us to focus on growth without the hindrance of a burn, and as we focused on that growth, listened to the customer, we understood that, hey, LA’s calling, LA’s calling. Thirteen million people, they need it. So we’re just really excited to work with a great group of people.”

In addition to giving SGMD a public mention, Walker noted that BudCars is looking for new brands — high-quality, compliant product that it can deliver to customers efficiently and safely within an hour or less. He also mentioned that BudCars is looking at establishing a series of kiosks throughout the community as well.

Cannabis Talk 101 is a top radio talk show focused on educating, advocating and defending members of the cannabis community as well as spreading the facts about cannabis while guiding and connecting industry professionals along the way.

BudCars is a retail business that offers same-day delivery of top-quality cannabis. Customers choose from a variety of products including edibles, flower, pre-rolls, vapes, tinctures and concentrate across dozens of premium brands. Once consumers complete their purchases online, they receive their order the same day via BudCars Cannabis Delivery Service.

Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes CarryOutsupplies.com and SugarRush(TM).

For more information, visit the company’s website at www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom

• Q3 2020 revenue numbers paint a bright future for KAVL with revenue up by approximately 44%
• Company closely focused on expanding distribution into large national retailers, convenience chains during Q4
• Much of Q3 activity centered around Bidi(TM) Sticks

Kaival Brands Innovations Group (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, recently released its Q3 financial report. The report showed revenues for KAVL up by approximately 44% compared to Q2 2020. In addition, the report noted that national distribution channels are being established for future growth.

“We had an extremely busy and fruitful third fiscal quarter,” said Kaival Brands president and CEO Niraj Patel. “We experienced a rising demand for our exclusively distributed premium product, the Bidi(TM) Stick. Our sales growth is occurring mostly organically through smaller distribution channels and wholesalers. . . . Now in the fourth fiscal quarter, we are more closely focused on expanding our distribution into large national retailers and convenience chains.”

According to the revenue report, revenues for Q3 were approximately $32.4 million, bringing the total revenues for the year thus far to nearly $54.9 million. Other numbers worth noting include gross profits for Q3 nearing $4.4 million, total cost of revenue – related party was approximately $28 million for the third quarter of fiscal 2020, and total operating expenses during the quarter reaching approximately $1.5 million. Net income for Q3 2020 was an estimated $2.6 million, and the company reported a cash balance of roughly $2.7 million as of July 31, 2020.

Much of the company’s activity centered around Bidi Sticks; Kaival Brands is the exclusive global distributor of the completely self-contained, disposable and recyclable product, designed to revolutionize the vaping experience.

“We are proud to announce that Bidi Sticks can now be found nationally in over 850 retail stores, like Fas Mart and SprintMart, in addition to over 2,200 current Circle K convenience stores,” Patel said. “And we expect in the coming months for our distribution to expand into thousands more retailers and convenience chains.”

Patel also noted that the innovative product is now available on the entire island of Guam, as an initial order valued at approximately $166,000 had been shipped to Ambros Inc. This Guam-based company is the exclusive distributor of SC Johnson and Budweiser products to all retailers located in that country. “The Bidi(TM) Stick will be the only vaping device offered by Ambros Inc. to their customers and retailers,” Patel said.

Made from high-quality components and equipped with a long-lasting battery and class C nicotine, the Bidi Stick is a self-contained, disposable product that is tamperproof and recyclable. Available in 11 flavors, the Bidi(TM) Stick includes sensitivity control system technology, offering a premium vaping experience for adult consumers only.

Kaival Brands is focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Kaival’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom

• Following $1.25 million donation, UC Berkeley launching Center for the Science of Psychedelics
• Pure Extract Technologies Inc. expanding into functional and medicinal mushroom market
• Psychedelic compounds increasingly being studied to treat wide range of physical, mental conditions
• Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell, functional mushroom products

For hundreds of years, medicinal mushrooms have been revered among both ancient and modern cultures throughout the world for their nutritional and medicinal qualities. Pure Extract Technologies, a private plant-based Canadian extraction company headquartered in British Columbia, is leveraging the latest in science in its goal to become the leading extraction company engaged in the development and commercialization of functional and medicinal products.

Psychedelics appear to be going mainstream, as evidenced by the planned launch of the UC Berkeley Center for the Science of Psychedelics following an anonymous donation of $1.25 million for startup costs. Last studied over 50 years ago, UC Berkeley is once again opening the doors to psychedelic research with an aim to study the possible medical benefits of psychedelic drugs, specifically the chemical compound psilocybin found in “magic” mushrooms.

“There’s never been a better time to start a center like this,” said UC Berkeley neuroscientist and co-founder David Presti. “The renewal of basic and clinical science with psychedelics has catalyzed interest among many people.”

Psychedelic compounds are increasingly being researched for possible benefits that include anti-tumor effects, improved immune function, anti-viral properties, mental wellness benefits and detoxification. Specific neurochemical-related conditions of particular interest to leading academic and medical research institutions include depression, anxiety, PTSD, obesity, narcolepsy, bipolar disorder, Alzheimer’s, OCD, ADHD and drug and alcohol addiction.

Psychedelics were granted FDA breakthrough therapy status for treatment-resistant depression in 2020 with approvals expected in 2021.

Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell and produce functional mushroom products in an EU-GMP-compliant environment, adequately positioning the Company to partner with organizations that plan to develop both functional and psychedelic products. Further solidifying the Company’s position on a global scale is its 10,000 square foot facility designed for EU-GMP certification that will enable sales throughout the world.

In addition to functional and medicinal products, Pure Extracts’ business model consists of three other verticals in connection with its existing cannabis and hemp extraction business. They include the marketing of in-house brands; toll processing – services in connection with the conversion of raw biomass into extracted oil products; and white labeling – the supply of products to existing brands looking to sell edibles, custom formulated oils and other cannabis-related products.

With a top spot among the fastest growing industries in North America, the mushroom industry is currently in a transitory phase whereby dry biomass is being converted to extracts. With a strong position in the industry, Pure Extracts is poised to benefit from this emerging trend as mushroom based products continue to enter mainstream awareness, bolstered by scientific research and ages-old therapeutic use.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom

• Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients
• Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients
• POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid clinical decision-making and lead to better health outcomes. The National Cancer Institute (“NCI”) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m) – a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector “AI hubs” designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).

A primary goal of precision cancer medicine is the accurate prediction of optimal drug therapies based upon the personalized molecular profiles of patient tumors; ideally, such predictions are based upon well-established molecular cause-and-effect relationships that are disrupted in cancer calls (https://ibn.fm/LQvQX). The foundation of these accurate predictions is built upon extensive bodies of data, with the volume of cancer-relevant data being generated and electronically stored on a daily basis vastly exceeding what could even be imagined only a few decades ago. As such, the search for significant correlations within cancer-relevant “big” datasets is a task which is ideally suited for artificial intelligence and machine learning-based approaches.

Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its unique real-world longitudinal data of drug-response and genomic profiles gathered from more than 150,000 de-identified cancer cases. Through its subsidiary Helomics, POAI is seeking to bring this cutting-edge technology to cancer research, where it is working with the pharmaceutical, diagnostic and biotech industries to develop predictive models of how tumors respond to drugs, which can be used both for clinical decision support and research into new therapies.

Meanwhile, the company’s wholly-owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells which can then be used to assist researchers and clinicians in identifying which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ proprietary Oncology Capture Technology Platform, which is able to grow the patient’s heterogeneous tumor sample in the laboratory, enabling oncologists to develop a patient-specific treatment plan (https://ibn.fm/byGJI).

Going forward, the use of artificial intelligence will help oncological researchers quickly understand how cancer cells become resistant to anti-cancer drugs, which can help improve drug development and adjust drug use. The technology can also be used to manage the use of chemotherapy drugs and predict a patient’s tolerance levels, thus allowing for chemotherapy regimens to be optimized. In the future, by leveraging Predictive Oncology’s AI-driven solutions, doctors will be able to make better-informed treatment decisions, thus reducing the need for unnecessary or poorly targeted treatments and improving patient outcomes.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020
• CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers
• Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members, Dr. Waldemar Priebe, Ph.D., and Dr. Sigmund Hsu, M.D., both of whom were involved in the Phase 1 trial of Berubicin, CNS Pharmaceuticals’ lead drug candidate.

Dr. Wen is a Neurology professor at Harvard Medical School and the Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute. Dr. Wen is a member of the Board of Directors of The Society for Neuro-Oncology and is also its immediate past President. An accomplished neuro-oncologist with a proven track record treating brain tumors and related neurologic complications, Dr. Wen is a graduate of University of London’s Medical College of St. Bartholomew’s Hospital. He continued his postgraduate internal medicine training with the University of London and completed his neurology residency with the Harvard-Longwood Neurology Training Program.

According to CNS Pharmaceuticals CEO John Climaco, Dr. Wen’s extensive experience in neuro-oncology will be invaluable to the company as it prepares for its upcoming Berubicin clinical trials. “The addition of Dr. Wen strongly complements our strategy to further drive the development of Berubicin as we look forward to initiating our pivotal Phase II trial in the U.S. and to working with our partner WPD Pharmaceuticals on the Phase I pediatric and Phase II adult studies in Poland,” Climaco added.

Dr. Wen’s appointment was included among the latest company updates furnished to the Securities and Exchange Commission on September 21, 2020. The investor presentation in the Form 8-K/A also announced that the company’s pivotal Phase 2 clinical trial for Berubicin in the United States is expected to begin in Q1 2021 (https://ibn.fm/MRaIq). In addition, Berubicin clinical trials in Poland (Phase 2 for adults and the first-ever Phase 1 trial for pediatric patients) are also due to begin on a similar timeline.

CNS Pharmaceuticals’ lead drug candidate is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. It is an organ targeted therapeutic that belongs to a class of cancer drugs called anthracyclines. CNS Pharmaceuticals has stated that it believes, based on limited clinical data, that Berubicin is the first drug in this class to cross the blood-brain barrier in adults, reaching the tumor cells of a patient with brain cancer.

Berubicin was developed by CNS Founder and Scientific Advisory Board member Dr. Waldemar Priebe, Ph.D., Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The development of Berubicin has been ongoing for over 15 years. The drug was granted Orphan Drug designation by the FDA for malignant gliomas in June 2020. CNS Pharmaceuticals is currently expected to make an Investigational New Drug (“IND”) submission to the FDA in Q4 2020.

In Phase 1 trials of Berubicin, conducted by Reata Pharmaceuticals (NASDAQ: RETA), 44% of GBM patients showed clinically significant response to Berubicin. A patient from the Phase 1 trial remains cancer-free following the trial treatment of Berubicin approximately 14 years ago.

CNS Pharmaceuticals plans for the Phase 2 adult trial in the United States to be adaptive, randomized, and controlled. These criteria for Phase 2 are intended to provide the data required for accelerated approval by the FDA. Additionally, the company plans to use the Phase 2 adult trial in Poland, conducted by sub-licensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1), to provide additional statistical support for the U.S. trial.

Plans are also in motion to begin Berubicin clinical trials for lymphomas, pancreatic, and ovarian cancers in 2021, which speaks to the high level of confidence CNS Pharmaceuticals has in Berubicin trials and its potential impact on the brain tumor therapeutics market. It is estimated that the global brain tumor therapeutics market will reach $3.4 billion by 2025, growing at a CAGR of 7.2 percent (https://ibn.fm/fqDvu).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• SRAX recently closed acquisition of LD Micro, leading micro-cap information portal
• LD Micro to become wholly-owned subsidiary of SRAX for 1.6 million in common stock plus $4 million cash
• Acquisition to accelerate adoption of Sequire, SRAX’s SaaS investment analytics platform
• Sequire revenue grew 29% year-over-year for Q2 2020, user base doubled to one million users during Q3 2020

SRAX (NASDAQ: SRAX), a data-based financial technology company, recently closed the acquisition of LD Micro, a leading data portal serving the small and micro-cap space. The deal, worth 1,600,000 shares of common stock and $4 million in cash, will make LD Micro a wholly-owned subsidiary of SRAX while maintaining founder Christopher Lahiji as president and appointing him to SRAX’s board of directors. The move comes during a rapid growth period for Sequire, SRAX’s data analytics SaaS platform. Geared towards the investment industry, Sequire unlocks data and insight for public companies that can be used to activate marketing campaigns to engage both new, existing and potential investors. Prior to acquiring LD Micro, SRAX had witnessed strong early success with Sequire. The platform doubled its user base to over one million investors and traders in two months (https://ibn.fm/j6oNa), in addition to posting Q2 earnings that showed a 29% increase in year-over-year revenue. The acquisition of LD Micro – a leading brand in the provision of exclusive information on micro-cap North American stocks – is expected to accelerate the adoption of Sequire while enhancing LD Micro’s own digital assets. Sequire helps public companies gain insights on the activities of both retail and institutional investors, providing critical actionable data to activate successful campaigns aimed to increase engagement with current investors while attracting new ones. Sequire’s application suite is currently being used by over 91 companies to harness the power of their data through the use of tools that leverage investor intelligence and outreach, track warrants, engage users through surveys, and promote events and roadshows. “The platform is an absolute game-changer for public companies and their shareholders,” said LD Micro founder Chris Lahiji in recent statements (https://ibn.fm/Mzz1z). “Both companies believe that one day executives will rely on Sequire the same way investors rely on Bloomberg.” “Over 1,500 companies have presented at LD Micro’s events since 2008, and almost all of them would be immediate beneficiaries of this technology,” he continued. The acquisition of LD Micro is expected to be immediately accreditive to SRAX’s operations. The recent LD 500 conference, held online in early September, included presentations from hundreds of companies across a wide range of industries in addition to featuring keynotes with some of the most prominent figures in the micro-cap world. The company continues to leverage the growing demand for quantifiable and detailed consumer data by creating specialized tools that empower companies to reveal core consumers and their characteristics across a wide range of industries. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Partnership allows space for significant exposure, growth over critical launch period
• AffPapa’s dedication to mission provides opportunities to broaden operator base, offer best services
• Mobius has already entered iGaming, eSports sectors with three differentiated brand offerings and hundreds of joint ventures with VIP and Master gaming affiliates

Mobius Interactive has announced a new partnership with AffPapa, a unique platform that allows operators and affiliates to find each other. In a recent announcement, Mobius and AffPapa noted the “well-timed collaboration” designed to ease the process of finding partners and overcome challenges (https://ibn.fm/AYlFm).

“By joining our affiliate site with the AffPapa global affiliate and operator partnership platform, MobiusAffiliates.com will be a valuable addition to its affiliate directory, allowing space for significant exposure and growth over its critical launch period,” said Mobius CEO Lynn Pearce.

“AffPapa has picked up its pace, venturing into new projects and developing our strategic objectives,” said AffPapa CEO Chris Chandler of the collaboration. “We at AffPapa think it’s the dedication to our mission that provides opportunities to broaden our operator base and continue offering the best services. I’m looking forward to a successful partnership.”

With the help of flexible filters, AffPapa helps each party search for the most relevant partner and find the best match within minutes. Both parties are gathered under one roof with the aim to ease the process of finding partners and overcome all impediments.

Looking forward to an official launch soon, Mobius has already entered the iGaming and eSports sector with three differentiated brand offerings and joint ventures with more than 600 VIP and Master gaming affiliates. The company’s management team has led the launch of more than 30 successful products within the last three years, and its partnership with UltraPlay is a key factor in this month’s kickoff.

Through UltraPlay, Mobius currently offers more than 34 unique games and sports betting available 24/7. Mobius’ sports betting product has a wide range of functionalities; it also offers mystery jackpots, cutting-edge tech and live and pre-match odds. In addition, the company’s live casino games are compatible with desktop, smartphone, laptop and tablet devices and can accommodate any number of players at any time.

Mobius Interactive is an online gaming operator featuring a variety of unique offerings catering to diverse demographic groups. Mobius Interactive’s team has extensive senior-management experience across business-to-consumer (“B2C”) and business-to-business (“B2B”) marketing in the iGaming industry, specializing in eSports, sports betting, casino and live casino. In partnership with leading and award-winning eSports and iGaming platform Ultra Play, Mobius Interactive seeks to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance engagement by leveraging state-of-the-art customer relationship management systems and joint ventures with more than 600 VIP and master-gaming affiliates.

For more information, visit the company’s website at www.MobiusInteractive.Ltd.

NOTE TO INVESTORS: The latest news and updates relating to Mobius are available in the company’s newsroom at http://ibn.fm/Mobius

• Company awarded government grant that could total $1.45 million to develop design for production of rare earth elements
• UUUU excited to play role in effort to develop domestic sources of rare earth production
• Energy Fuels announced entry into REE sector earlier this year, ideal complement to company’s other rare earth initiatives

Energy Fuels (TSX: EFR) (NYSE American: UUUU), a leading producer of uranium in the United States, along with a team from Penn State University has been awarded a government grant for an initial amount of $150,000 to develop a design for the production of rare earth elements (“REE”) from coal-based resources (https://ibn.fm/kMbwJ). The contract was awarded by the U.S. Department of Energy (“DOE”) Office of Fossil Energy (“FE”) and the National Energy Technology Laboratory (“NETL”). If Energy Fuels is successful at the conceptual design phase, the DOE could award Energy Fuels an additional $1.3 million to complete a feasibility study.

“We are excited to have the opportunity to work with the DOE office of Fossil Energy, the National Energy Technology Laboratory, and Penn State on this important rare earth initiative,” said Energy Fuels president and CEO Mark S. Chalmers. “Energy Fuels has been carrying out substantial work over the past year to explore the potential for implementing a commercial rare earth recovery and processing program at our White Mesa Mill. This initiative to produce REOs from coal-based resources is complementary to our ongoing efforts and will potentially broaden the sources of REE feedstock available to us in the future. We also hope this project opens the door for us to work with the DOE and other agencies on future rare earth initiatives.”

The contract calls for Energy Fuels and a team of experts from Penn State to evaluate and develop a conceptual design to allow for the commercial production of mixed rare earth oxides from coal-based resources in an environmentally benign fashion. In addition, the contract also notes that DOE may award Energy Fuels a contract for the completion of a feasibility study on this initiative.

The DOE has already demonstrated the technical feasibility of extracting rare earth elements from coal and coal-based resources, but the department is looking to fast-track the advancement of commercially viable technologies to produce REEs from coal-based resources, including coal refuse, over/under burden materials, power generation ash and others.

Earlier this year, Energy Fuels announced its entry into the REE sector, noting that it believes its fully licensed and constructed White Mesa Mill could play a key role in bringing the REE supply chain back to the U.S. from China (https://ibn.fm/UEB25). The company applied for the DOE/NETL grant in June, in part because the REE minerals contained in these coal-based resources are similar to the REE minerals contained in other materials UUUU is evaluating as part of its REE program.

The contract provides initial funding for Energy Fuels and the Penn State team to complete a detailed conceptual design and flowsheet for the possible commercial operation of a facility that produces REOs from coal-based resources. Once that is complete, the DOE will determine whether to provide additional funding for the development of a feasibility study. It is also possible that the DOE could participate in the funding of a facility that performs this work.

“Rare earths are used in a host of advanced and everyday technologies, including cell phones, computers, renewable energy generation, batteries, automobiles, and military applications,” said Chalmers. “However, the U.S. does not currently have a fully integrated rare earth supply chain. Therefore, the government has made it a priority to assist in the development of domestic sources of rare earth production. With this award, we are excited to play a role in this effort, while also pursuing our other complementary rare earth initiatives. We also hope this DOE program puts Energy Fuels on the radar for other U.S. government rare earth initiatives.”

Based in Lakewood, Colorado, Energy Fuels holds three of America’s key uranium production centers: the Nichols Ranch (ISR) project in Wyoming, the Alta Mesa ISR Project in Texas and the White Mesa Mill in Utah – the only conventional uranium mill operating in the United States today. Together, these facilities have a licensed capacity of more than 11.5 million pounds of U3O8 per year. With an asset portfolio that boasts more uranium production facilities, in-ground resources, production capacity and experienced personnel than any other producer, Energy Fuels is in a unique position to maintain its position as the leading producer of uranium in an era of viable transformation of the U.S. nuclear industry.

For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• BFGC lays out road map to success
• Potential of area highlighted as majors show interest
• Drill results encourage further exploration
• Gold price maintains lofty levels

The virtual investor presentation given by Bullfrog Gold (CSE: BFG) (OTCQB: BFGC) (FSE: 11B) at the Aug. 6 OTCQB Virtual Investor Conference laid out BFGC’s well-thought-out road map to becoming a profitable gold producer. Bullfrog was one of several companies carefully selected to present to individual and institutional investors, advisors and analysts attending the event.

Starting with a brief account of BFGC’s earliest acquisitions, CEO David Beling went on to show the exciting potential the Bullfrog Mining District of Nevada, location of the company’s properties, has. He also discussed the company’s current drilling program, which has returned promising results. With gold prices at the level they are now — above $1,900 an ounce —Bullfrog seems to be in the right business at the right time.

The presentation noted that the company started trading in the year 2011 and it acquired a strategic land position adjacent to Barrick Bullfrog Inc. in Nevada’s Bullfrog Mining District (the District).  Now, the company has commanding land and resource positions in an area that has, in the past, proved highly productive and is surrounded by several major land holders successfully exploring in one of the most prolific gold exploration areas in the US

Beling also explains that Bullfrog’s property positions lie about four miles to the west of Beatty, a town of about 1,000, in Nevada. The Bullfrog area is well-developed for industrial purposes, with substantial infrastructure that includes several roads, a paved highway up to the front gate of the BFGC properties, plus a power line and substation on the site. BFGC properties include the Bullfrog pit, the adjacent Mystery Hill area, the Montgomery-Shoshone pit.   and the company’s new Paradise Ridge exploration target.

From 1989 to 1999, Barrick Bullfrog, using conventional milling, recovered 2.329 million ounces of gold. The average grade to the mill was 3 g/t, with underground ore averaging over 8 g/t. Barrick used cutoff grades of 0.5 g/t for pits and 3.0 g/t for underground. Its operations ceased in 1999 when reserves were depleted and at a time when gold was trading at significantly less than $300/ oz.

BFGC is not the only outfit that thinks there’s still more gold to be found in region. In October 2018, Coeur Mining put out $90 million to acquire Northern Empire, which has properties in the District (https://ibn.fm/sm5co). And in May this year, AngloGold Ashanti, the world’s third-largest gold mining company, committed $3 million to purchase certain properties in the District from Renaissance Gold (https://ibn.fm/V7O5N). Other companies operating include Kinross Gold, which has staked several hundred claims, and Corvus Gold, which continues to expand its large land and resource positions.

BFGC’s current project resources estimated in 2017 by Tetra Tech were 525,000 oz. of measured and indicated heap leachable gold resources averaging 1.02 g/t and 111,000 oz. of inferred resources at 1.2 g/t. The Tetra estimates were based on a recovery of 72%. However, CEO Beling noted that metallurgical sampling and testing programs during the past two years achieved an average 86% gold recovery.

BFGC’s 2020 drilling program involved 25 holes in total, of which 17 were designed to expand resources and the Bullfrog pit limits toward the northeast in Mystery Hill area. Now, Beling observed, there is enough close-spaced holes to convert most of BFGC’s “inferred resources” to “measured and indicated resources” and expand resource along strike and down dip in this area.

Six holes  were designed and  drilled in the Montgomery-Shoshone area to expand resources and pit limits in this area, which is about one mile to the northeast of the Bullfrog pit. , Hole 22 had 80 ft. of mineralization at 0.54 g/t while Hole 21 had 200 ft. of mineralization at 0.78 g/t. Importantly, the nearest hole from mineral intercept in Hole 22 is approximately 600 ft. to the northeast, thereby providing very good potential for further expansions of mineralization and perhaps the pit.

Although the two holes drilled at the far south end of the Paradise Ridge Target did not intersect mineralization, only about 4% of the area was drill tested while still having good exploration potential for 2,000 meters to the northwest. In summary, BFGC achieved success both in defining the limits of its resources and its pits.

For more information, visit the company’s website at www.BullFrogGold.com.

NOTE TO INVESTORS: The latest news and updates relating to BFGC are available in the company’s newsroom at http://ibn.fm/BFGC

• Surging viewership numbers on online streaming platforms, capacity constraints amongst legacy film studios have led to increased need for new facilities
• A number of new film studios have recently been commissioned, including ones in Montana and Long Island
• The Movie Studio is only major independent film studio in South Florida, placing it in ideal position to benefit from surge in demand for original content production

The Movie Studio (OTC: MVES), an independent Florida-based film studio, is set to benefit as a surge in demand for movie and television content has led to an increased need for film studios. With COVID restrictions across the globe leading to an exponential increase in OTT viewing figures, streaming companies such as Netflix and Disney+ are reporting record growth in their subscriber bases while newcomers including NBCUniversal’s Peacock and AT&T’s HBO Max are racing to develop original content programming which can be used to entice users to their platforms (https://ibn.fm/7b39G).

Parviz Farahzad, a Nassau County-based real estate developer, has recently struck a financing deal to construct a new film studio on Long Island, as demand for new content development and social distancing have led to a newfound need to build outside of the traditional California studio enclaves where films and tv shows have been habitually filmed in the past.

“I am delighted that the IDA is able to assist in bringing a third fully approved NYS sound studio to Nassau County, just as the film and television industry is making its comeback – with major players like HBO, Apple TV, Netflix and NBC all with projects in the works,” said Nassau County Executive Laura Curran.

In a separate deal announced in early September, media company Shadowcast Partners announced that they would build a $20 million studio-grade sound stage for television and film production in Missoula, Montana, describing the soon-to-be-built “Montana Media Hub” as an asset class that’s in high demand but is lacking supply (https://ibn.fm/N9oKT).

“This is really focused on television and film production, but it could also include streaming platforms such as Netflix, Amazon and Apple, or large network and cable giants like Paramount, Warner Brothers and Hallmark,” said Graham. “We think Montana is poised with the right investment to establish a strong new industry in the state due to the MEDIA Act and tax incentives passed last year.”

Based in Fort Lauderdale and founded in 1961, The Movie Studio Inc. is the only major independent film studio located in South Florida. Having previously produced and distributed major motion pictures in the state such as ‘Exposure’, ‘Bad Actress’ and ‘Dancing on the Edge’, The Movie Studio is now engaging in the pre-production of its next film, Cause & Effect, a Miami street movie about the seedy underbelly of South Florida nightlife, and has also begun pre-production on Pegasus, a family movie about a young girl and a horse which is planned to be their “signature film” (https://ibn.fm/XlwOL).

With the demand to produce and film original media content facing challenges from capacity constrained Hollywood studios, The Movie Studio’s unique business model and Florida location has positioned the company to benefit from the wave of growth within the OTT industry.

“The Movie Studio fulfills our objective as we enter the second tier of the digital revolution,” stated MVES president and CEO Gordon Scott Ventures. “We have confidence in the value proposition of the brand and our acceleration into the exploding digital motion picture universe.”

For more information, visit the company’s website at www.TheMovieStudio.com.

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES